New Elemental Impurities Tests for Pharmaceutical Products According to the New ICH Q3D and USP 232/233 Guidelines

New Elemental Impurities Tests for Pharmaceutical Products According to the New ICH Q3D and USP 232/233 Guidelines is a webinar dedicated to the new elemental impurities test requirements as per new ICH Q3D and USP 232/233 Guidelines, how to do risk assesment.

New Elemental Impurities Tests for Pharmaceutical Products According to the New ICH Q3D and USP 232/233 Guidelines covers topics such as:

  • Regulatory status: FDA, ICH Q3D, USP 232/233
  • Elemental Impurities: The case for change
  • What drug products are within the scope of the guidance
  • Scope of the new guidance on Elemental Impurities - related to ICH Q3D and USP Chapters 232 and 233
  • How risk assessment influences what testing is required
  • Which classes of drug products need to comply with ICH Q3D and which with USP 232/233
  • Implementation of the Guidelines
  • What documentation related to control of elemental impurities is expected by FDA
  • Analytical Procedures and how methods should be validated
  • Which procedures can be used to demonstrate compliance
  • What you should be doing now?

New Elemental Impurities Tests for Pharmaceutical Products According to the New ICH Q3D and USP 232/233 Guidelines intended for attendees from:

  • Laboratory Managers/ Directors / Supervisors
  • Researchers/ R&D Mangagers
  • Analytical Chemists
  • Laboratory Technicians / Operators
  • Regulatory Compliance Managers
  • Laboratory Managers
  • Chemical Manufacturing and Control managers
  • Quality Control and assurance managers

Future Events

New Elemental Impurities Tests for Pharmaceutical Products According to the New ICH Q3D and USP 232/233 Guidelines 2020

Important

Please, check the official conference website for possible changes, before you make any traveling arrangements

Prices are for evaluation only.

Other Events with Similar Categories

Other Events with Similar Location or Organizer